<DOC>
	<DOCNO>NCT02035020</DOCNO>
	<brief_summary>The primary objective study investigate whether treatment IFN gamma induce significant accumulation frataxin FRDA patient , possibility suggest pre-clinical evidence animal model disease .</brief_summary>
	<brief_title>A Phase IIa Trial Test Safety Efficacy Interferon Gamma Treatment Elevating Frataxin Levels FRDA Patients</brief_title>
	<detailed_description>This Phase 2 clinical trial . A total 10 FRDA patient recruit All subject treat dose 100-150-200-micrograms IFN gamma 1b ( Imukin® ) subcutaneously , interval 14 day , total 3 injection .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>1 . FRDA patient diagnosis genetically confirm . 2 . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect study . 3 . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . 4 . Male and/or female subject age &gt; 18 &lt; 45 year 1 . Pregnant breastfeed woman . 2 . Significant concurrent medical condition time screen baseline visit , include , limited , follow : Any major illness/condition evidence unstable clinical condition ( eg , renal , hepatic , hematologic , GI , endocrine , pulmonary , immunologic , local active infection/infectious illness ) , investigator 's judgment , substantially increase risk subject participates study . Class III IV congestive heart failure define New York Heart Association . Acute coronary syndrome ( eg , myocardial infarction , unstable angina pectoris ) history significant cerebrovascular disease within 24 week screen . 3 . Presence transplant organ . 4 . Previous assumption IFN gamma 1b . 5 . Abnormality hematology chemistry profile value screen : Positive hepatitis B surface antigen ( HBsAg ) , Total hepatitis B core antibody ( HBcAb ; also call anti HBc ) , and/or hepatitis C antibody ( HCVAb ) confirmation hepatitis C virus ribonucleic acid ( HCV RNA ) . ALT/AST level &gt; = 1.5X ULN . Total bilirubin level &gt; = 1.5 time ULN . Hemoglobin level &lt; = 80 gL ( 8.0 g/dL ) . Platelet count &lt; = 100 x 109/L ( 100,000 cells/mm³ ) &gt; = 1000 x 109/L ( 1,000,000 cells/mm³ ) . White blood cell count &lt; = 3.5 x 109/L ( 3500 cells/mm³ ) . Absolute neutrophil count ( ANC ) &lt; 2000 cells/mm³ . Serum creatinine level &gt; = 177 μmol/ L ( 2 mg/dL ) . Glycosylated hemoglobin ( HbA1c &gt; 10 % ) . 6 . Current history serious psychiatric disorder alcohol drug abuse . 7 . Participation study within 30 day screen and/or study participation . 8 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation ability comply study procedure , investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>frataxin , gamma interferon , Friedreich ataxia</keyword>
</DOC>